Innovating Cure & Care to make patients’ lives better

Zambon Group
The group

We are a modern chemical-pharmaceutical company, founded on the history and values of an Italian family owned enterprise, with ambitious plans for growth


The Group

We look to the future, researching new cure and treatment solutions for specialized diseases such as Parkinson's and severe respiratory disease

Zambon USA Ltd.

Zambon’s Presence in the USA

Over the past few years, we have been steadily building our presence in the US through acquisition, R&D efforts, collaborative partnerships, and relationships with top scientific leaders, policymakers and patient organizations.

Thibaud Eckenschwiller

Interview with CEO & President

Our BOSTON and PROMIS programs are of utmost importance in the US and globally since BOS and NCFB are severe respiratory diseases. The unmet need is very high and urgent as there are no approved treatments currently indicated for these patients.




Bronchiolitis Obliterans Syndrome (BOS) is a rare and severe respiratory disease that commonly affects people following lung or allogeneic hematopoietic stem cell transplant.



Non-cystic Fibrosis Bronchiectasis (NCFB) is a serious respiratory disease characterized by chronic inflammation, wall thickening and dilatation of the airways.

WOrk with us

Work with us

We want people who make the difference through a make-it-happen approach based on company ethics. We recognize merits, developing talents and taking good care of our people.

Woman reading online news on digital tablet

News & Media

  • Positive Results from Phase 3 PROMIS-I Study of CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at European Respiratory Society (ERS) Annual Meeting
    Read more
  • Key data on economic impact of BOS presented at ISHLT 2021 
    Download presentation

View additional News & Media